RhoA regulates invasion of glioma cells via the c-Jun NH2-terminal kinase pathway under hypoxia

Oncology Letters

Volumn 4, Issue 3, 2012, Pages 495-500

  Tong, Jiao Jian ^a   Yan, Zhang ^a   Jian, Ren ^a   Tao, Huang ^a   Hui, Ouyang Tao ^a   Jian, Chen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cell invasion; Glioma; Hypoxia; Matrix metalloproteinase 2; RhoA JNK signaling pathway; U251 cell line

Indexed keywords

GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER INVASION; CELL ASSAY; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE SILENCING; GERANYLGERANYLATION; GLIOMA CELL; HUMAN; HUMAN CELL; HYPOXIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 84863880222     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.777     Document Type: Article

References (30)

1. Loeper S, Romeike BF, Heckmann N, Jung V, Henn W, Feiden W, Zang KD and Urbschat S: Frequent mitotic errors in tumor cells of genetically microheterogeneous glioblastomas. Cytogenet Cell Genet 94: 1-8, 2001.
2. Wu M, Chen Q, Li D, Li X, Li X, Huang C, Tang Y, Zhou Y, Wang D, Tang K, et al: LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways. J Cell Biochem 103: 245-255, 2008.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
4. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DM, Cavenee WK and DePinho RA: Malignant glioma: genetics and biology of a grave matter. Gene Dev 15: 1311-1333, 2001.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352: 987-996, 2005.
6. Hockel M, Schlenger K, Aral B, et al: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-4515, 1996.
7. Woodhouse EC, Chuaqui RF and Liotta LA: General mechanisms of metastasis. Cancer 80: 1529-1537, 1997.
8. Van Noorden CJ: Proteases and protease inhibitors in cancer. Acta Histochem 100: 344-354, 1998.
9. Sternlicht MD and Werb Z: How matrix met alloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516, 2001.
10. Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, et al: Active matrix met alloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 8: 2894-2901, 2002.
11. Egeblad M and Werb Z: New functions for the matrix met alloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
12. Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, et al: Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix met alloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 79: 1828-1835, 1999.
13. Vogt A, Sun J, Qian Y, Hamilton AD and Sebti SM: The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21 (WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem 272: 27224-27229, 1997.
14. Laufs U and Liao JK: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271, 1998.
15. Noguchi Y, Nakamura S, Yasuda T, Kitagawa M, Kohn LD, SaitoY and Hirai A: Newly synthesized RhoA, not Ras, is isoprenylated and translocated to membranes coincident with progression of the G1 to S phase of growth-stimulated rat FRTL-5 cells. J Biol Chem 273: 3649-3653, 1998.
16. Wong WW, Dimitroulakos J, Minden MD and Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16, 508-519, 2002.
17. Graaf MR, Richel DJ, van Noorden CJ and Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev. 30, 609-641, 2004.
18. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, VannierJP, Soria J and Soria C: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22: 1139-1148, 2001.
19. Sawada K, Morishige K, Tahara M, Kawagishi R, Ikebuchi Y, Tasaka K and Murata YL: Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res 62: 6015-6020, 2002.
20. Kusama T, Mukai M, Tatsuta M, Nakamura H and Inoue M: Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho. Int J Oncol 29: 217-223, 2006.
21. Sullivan R and Graham CH: Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 26: 319-331, 2007.
22. Fujiwara S, Nakagawa K, Harada H, Nagato S, Furukawa K, Teraoka M, Seno T, Oka K, Iwata S and Ohnishi T: Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol 30: 793-802, 2007.
23. Bruland OS, Hoifodt H, Saeter G, Smeland S and Fodstad O: Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 11: 4666-4673, 2005.
24. Coussens LM, Fingleton B and Matrisian LM: Matrix met alloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392, 2002.
25. Egeblad M and Werb Z: New functions for the matrix met alloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
26. Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, et al: Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix met alloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 79: 1828-1835, 1999.
27. Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS, Lee SH, Park IC, Rhee CH and Hong SI: Ionizing radiation enhances matrix met alloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 66: 8511-8519, 2006.
28. Arias J, Alberts AS, Brindle P, Claret FX, Smeal T, Karin M, Feramisco J and Montminy M: Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. Nature 370: 226-229, 1994.
29. Bannister AJ, Oehler T, Wilhelm D, Angel P and Kouzarides T: Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro. Oncogene 11: 2509-2514, 1995.
30. Fromigué O, Hamidouche Z and Marie PJ: Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem 283: 30549-30556, 2008.